Kari Gran Inc. released OTC SPF sunscreen drugs without adequate batch testing or stability data.
What happened
FDA inspected Kari Gran Inc.'s drug manufacturing facility in Seattle from July 5 to July 8, 2022. The agency found the company released multiple batches of OTC SPF sunscreen drug products without adequate testing of zinc oxide, the active ingredient, without routine finished-product or microbiological testing, and without adequate stability data. FDA also cited missing component identity testing, inadequate process validation, incomplete batch records with white-out and unsigned changes, and weak quality-unit oversight; it reviewed the company's July 28, 2022 response and found it inadequate.
What FDA found
Failed to test each batch before release for identity and strength of the active ingredient, zinc oxide, and failed to have a stability program to set storage conditions and expiration dates.
21 CFR 211.165(a) and 21 CFR 211.166(a)Failed to test incoming components for identity and to validate supplier test results before relying on their certificates of analysis.
21 CFR 211.84(d)(1) and (2)Failed to validate manufacturing processes, including critical variables such as mixing time and temperature.
21 CFR 211.100(a)Batch production records were incomplete and contained white-out and crossed-out entries without signature, date, or explanation.
21 CFR 211.188The quality control unit did not adequately oversee operations, including annual product review, complaint handling, and labeling, and one finished batch lacked a lot number and expiration date.
21 CFR 211.22
What FDA wants
FDA tells Kari Gran to correct the violations promptly and respond in writing within 15 working days with corrective actions, including testing retained samples, independent assessments, and CAPA (corrective and preventive action) plans; if it cannot finish in that time, it must give reasons and a completion schedule.
Who should pay attention
- brands selling zinc oxide SPF sunscreens
- retailers and distributors of OTC topical drug products
- small drug manufacturers that rely on supplier certificates of analysis
This is a summary. Read the original letter on fda.gov.